32 results
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
, stockholders holding Shares as part of a straddle, hedging, constructive sale or conversion transaction, stockholders that purchase or sell Shares as part
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
not currently manage its foreign currency exposure through hedging programs and will continue to monitor its foreign currency assets and liabilities and evaluate … purposes. The Company does not currently manage interest rate exposure through hedging programs. The Company will continue to monitor and evaluate the need
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
that the foregoing restrictions preclude the undersigned from engaging in any hedging or other transaction which is designed to or which reasonably could be expected … the undersigned. Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right
424B5
2k8lxa55800n
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
ii106zwi dgtv5lwq42
13 Sep 22
Prospectus supplement for primary offering
5:19pm
424B3
xcjp mcxq11
11 Jul 22
Prospectus supplement
4:32pm
POS AM
heyntovznfvext4c
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
424B3
odgfj hnehpjkc
13 May 22
Prospectus supplement
8:18am
DEF 14A
sikbt
28 Apr 22
Definitive proxy
8:36am
424B3
hpnwytd7r9bhzyksvrqz
31 Mar 22
Prospectus supplement
11:42am
POS AM
ble1777 d7ivm
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
710q4 jv9z8
12 Nov 21
Prospectus supplement
8:41am
424B3
2sh7q4rs6h5ci76dc3cg
13 Aug 21
Prospectus supplement
5:25pm